Curovir is a privately-held Swedish biopharmaceutical company founded in 2017 as a spin-off from Apodemus AB. The company is dedicated to the development of novel antiviral drugs for EV infections. Curovir also evaluates the effect of pleconaril in type 1 diabetes in collaboration with researchers at Oslo University Hospital. Pleconaril is an EV antiviral substance that was previously developed for the common cold.
Curovir is a family business managed by Johan Claesson, a Swedish businessman. Mr. Claesson is active in several sectors, including finance, real estate, energy, farming and pharma.